Avengers Assemble! A Day in the Life of the BSC Technical Working Groups

Connie Mitchell, MS Joe Dever, PhD, DABT



Technical Working Groups


- Technical Working Groups are the **core** technical entities responsible for designing and executing the BSC's scientific mission.
- Focused on specific scientific questions related to evaluation of botanical ingredient safety, as defined by each TWG's mission and objectives.
- Being apart of a TWG involves
 - participating in teleconferences;
 - providing technical and strategic input and perspectives during the TWG's ongoing scientific discussions;
 - experimental research;
 - data analysis;
 - writing;
 - communicating on behalf of the TWG.
- Sub-teams within a TWG may be formed as needed on key topics related to the overall TWG mission & objectives.



Technical Working Groups: Composition & Process


- TWG members may be nominated by BSC Steering Committee, Stakeholder Council members, TWG members, themselves, or staff.
- Eligibility for TWG participation will be evaluated by the BSC Steering Committee and TWG co-chairs based on scientific and technical expertise via submission of an application and CV.
- As is feasible, all TWGs will **strive for balance across sectors** (public / private), areas of expertise, and geography.
- Members of the TWG will review membership on a yearly basis

Botanical Safety Consortium Objectives



SAFETY CONSORTIUM


Botanical Safety Consortium Strategy



- Develop a list of botanical ingredients that have available safety information
- Create a reference botanical ingredient library
- Utilize analytical approaches and chemometrics for adequate characterization
- Develop strategies to address variability between botanical ingredients for safety assessment
- Identify suitable in vitro/in silico assays that are within the identified domain of applicability for botanicals
- Evaluate the botanical reference ingredients in a battery of selected in vitro/in silico assays
- Make data publicly available
- Perform suitable data analysis
- Compare the results from the testing battery to existing animal and human safety data
- Leverage learnings to determine suitable *in vitro* & *in silico* approaches for botanical evaluation
- Identify challenges for botanical application
- Prioritize research and evaluation needs




Technical Working Groups






Traditional Botanical Safety Paradigm



Modern Botanical Safety Paradigm



Technical Working Groups – Current status

- Formation of teams of experts for each of the focus areas
 - Balance of industry, government, and academic scientists
 - Global representation, where possible
- Refining goals and objectives
- Reviewing the state of the science on botanicals research in each of the key areas







Chemical Analysis Mission: To develop a strategy and methodologies to characterize botanical ingredients for the purpose of enabling safety assessments.

- Prioritize selected candidates for comprehensive chemical characterization based on the needs of other Technical Working Groups;
- Identify a strategy to compile existing literature on analytical methods used and chemical composition of selected botanical ingredients;
- Select resource-efficient analytical approaches, methods, and partners that can comprehensively characterize botanical ingredients with respect to safety, including, but not limited to, identifying and quantifying constituents of botanicals to the degree required for material selection and safety assessment.



Chemical Analysis

Current Members

- Rajiv Agarwal (FDA)
- Tim Baker (co-chair, P&G)
- Nadja Cech (UNC Greensboro)
- Kan He (Herbalife Nutrition)
- Ikhlas Khan (University of Mississippi)
- Adam Kuszak (NIH/OĎ)
- Eike Reich (HPTLC-Association)
- Catherine Rimmer (NIST)
- Elan Sudberg (Alkemist Labs)
- Micheal (Bhodi) Tims (Maryland University of Integrative Health)
- Richard van Breemen (Oregon State University)
- Suramya Waidyanatha (co-chair, NIEHS)
- Hong You (Eurofins)
- Yanjun Zhang (Herbalife Nutrition)




Genotoxicity Working Group Mission: To develop a screening strategy that can reliably identify potential genotoxic botanical ingredients, with future application to evaluate associated human health risks

- Select resource-efficient in silico and in vitro tools that can identify genotoxic agents in complex mixtures represented by botanical ingredients;
- Recommend criteria for identifying significant genotoxic hazards;
- Select candidate botanical ingredients based on suspected toxicity or safety with respect to genotoxicity endpoints;
- Use a series of botanical case studies to evaluate the usefulness and reliability of a growing genotoxicity toolbox in the context of *in vivo* outcomes and exposure (where such data are available).



Genotoxicity Working Group Members


- Gerhard Eisenbrand (Consultant)
- Jim MacGregor (Consultant)
- Nan Mei (FDA/NCTR)
- Stefan Pfuhler (co-chair, Procter & Gamble)
- Ivonne Rietjens (Wageningen University)
- Stephanie Smith-Roe (NIH/NIEHS)
- Helga Stopper (University of Wurzburg)
- Kristine Witt (co-chair, NIH/NIEHS)
- Dan Xi (NIH/NCI)



Hepatotoxicity Working Group Mission: To

develop a screening strategy that can reliably identify hepatotoxic botanical ingredients, inform mechanisms of toxicity, and characterize the 'botanicokinetic' properties of botanical ingredients.

- Select resource-efficient *in silico* and *in vitro* tools that can accommodate complex mixtures represented by botanical ingredients. These tools will estimate human liver potential or ADME properties;
- Select candidate botanical ingredients with respect to hepatotoxicity based on suspected toxicity or safety, and ADME endpoints;
- Evaluate the potential and limitations of these tools to predict and understand botanical ingredient -induced hepatotoxicity;
- Explore the potential of drug-botanical interactions using candidate methods.



Hepatotoxicity Working Group Members

- Dennis Cladis (Purdue University)
- Stephen Ferguson (co-chair, NIH/NIEHS)
- Shabana Khan (University of Mississippi)
- Igor Koturbash (U of Arkansas for Medical Sciences)
- Katelyn Lavrich (NIH/NIEHS)
- Albert Li (In Vitro ADMET Laboratories)
- Yitong Liu (FDA)
- Scott Masten (NIH/NIEHS)
- Merrie Mosedale (UNC)
- Amy Roe (co-chair, Procter & Gamble)
- Mathieu Vinken (Vrije Universiteit Brussel)
- Heather Walker (Bayer)
- Paul Walker (Cyprotex)
- Charles Wu (FDA/CDER)



ADME Group

- Will work with all technical working groups to obtain knowledge on toxicokinetic properties of botanical constituents
 - Metabolites need to be examined for potential toxicity



Developmental and Reproductive Toxicity Working Group Mission: To develop screening strategies that can reliably identify potential developmentally or reproductively toxic botanical ingredients.

- Select in silico and in vitro tools that can accommodate complex mixtures represented by botanical ingredients;
- Select candidate botanical ingredients based on suspected toxicity or safety with respect to DART endpoints;
- Establish a series of DART botanical case studies, such that we can evaluate the usefulness of a growing toolbox.



Developmental and Reproductive Toxicity Working Group Members

- Mark Cronin (Liverpool John Moores University)
- Corrado Galli (University of Milan)
- Amy Inselman (FDA/NCTR)
- Catherine Mahony (co-chair, Procter & Gamble)
- Raymond Pieters (Utrecht University)
- John Rogers (US EPA)
- Vicki Sutherland (co-chair, NIH/NIEHS)



Systemic Toxicity Mission: To develop tools that can reliably identify botanical ingredients with the potential to induce adverse effects within multicompartmental biological systems

- Develop systematic literature review strategies and tools to efficiently gather existing history of use and traditional use data for botanical ingredients.
- Select and leverage multi-compartmental in vitro models to generate systemic safety data for botanicals
- Improve *in vitro* to *in vivo* extrapolation (IVIVE) using toxicokinetic modeling to support safety assessments and margin of safety calculations



Systemic Toxicity Working Group Members

Current Members:

- Steven Dentali (Dentali Botanical Sciences)
- Joe Dever (co-chair, Amway)
- Esther Haugabrooks (PCRM)
- Michael Lawless (Simulations Plus)
- Annie Lumen (FDA)
- Jim McKim (IONTOX)
- Bhashkar Mukerji (Givaudan)
- Jürgen Schnabel (Givaudan)
- Nisha Sipes (co-chair, NIH/NIEHS)
- Sibyl Swift (NPA)



Data Analysis Mission: To develop and apply data analytic methods that use *in vitro/in silico* data for safety/hazard assessment of botanical ingredients

- Work with other Technical Working Groups to design experiments;
- Support the data analysis needs of other Technical Working Groups;
- Development, evaluation and/or application of data analysis methods for the determination of botanical ingredient sufficient similarity;
- For a subset of botanical ingredients, characterize the degree of similarity between the toxicological profiles derived from *in vitro/in silico* data compared to those obtained from traditional animal tests



Data Analysis Working Group Members

Current Members:

- Scott Auerbach (co-chair, NIH/NIEHS)
- Minjun Chen (co-chair, FDA)
- Laura Egnash (Consultant)
- Dagney McCready (Eurofin)
- Andrew Nguyen (PISC)
- Julia Rager (University of North Carolina)
- David Reif (co-chair, North Carolina State University)

Botanical Candidate Criteria

Each toxicity endpoint TWG will select botanical ingredient candidates (6-8) Selection based on evidence of toxicity or safety from scientific findings in humans, animals, or alternative methods

All the botanical ingredients will be compiled into a master list and will undergo chemical analysis

> The master list of botanical ingredients will be tested in all the assays by all toxicity endpoint groups


Result will be made public via publications



Methodology Criteria and Considerations

- Focus on *in silico* and *in vitro* methodologies
- Establish as suitable for botanicals (mixtures)
- Leveraging history of use data for individual botanicals
- In vitro to in vivo extrapolation
- **Practicality** (cost, time and technical requirements)





Other Potential Groups

- Cardiotoxicity
- Immunotoxicity
- Nephrotoxicity
- Neurotoxicity
- Others?



- The BSC has established 6 technical working groups to execute the TWG's mission and objectives.
- We thank all current and future TWG members for their dedication, time, expertise, and determination.

Captain America: "We need a plan of attack!" Iron Man: "I have a plan. Attack!"

